Furthermore, in pancreatic cancer, where ICB has shown little efficacy, a more recent study showed that a small subset of patients with ARID1A alterations achieved an objective response, including a complete remission after immunotherapy treatment, thus warranting prospective trials (ClinicalTrials.gov, NCT02478931) [66]. The gene discussed is ARID1A; the disease is pancreatic neoplasm.